Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $101.29 USD
Change Today +3.39 / 3.46%
Volume 656.1K
ALNY On Other Exchanges
As of 3:58 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Barry E. Greene

President and Chief Operating Officer,Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 42 board members in 3 different organizations across 6 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Barry E. Greene has been the President and Chief Operating Officer at Alnylam Pharmaceuticals, Inc. since December 12, 2007 and October 2003 respectively. Mr. Greene has more than 20 years of experience in the healthcare, pharmaceutical and biotechnology industries. Mr. Greene joined Alnylam in 2003 and has over 15 years of experience in the healthcare industry. He served as the Principal Financial Officer and Principal Accounting Officer of Alnylam Pharmaceuticals ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

Director, Chairman of Ad Hoc Business Development Committee and Member of Compensation Committee
Director, Chairman of Compensation Committee and Member of Audit Committee


University of Pittsburgh

Other Affiliations*

Annual Compensation*

Total Annual Compensation$515,000

Stock Options*

All Other Compensation$7,956
Exercised Options64,800
Exercised Options Value$5,275,081
Exercisable Options641,500
Unexercisable Options142,500
Total Value of Options$5,275,081
Total Number of Options878,800

Total Compensation*

Total Annual Cash Compensation$798,956
Total Short Term Compensation$515,000
Other Long Term Compensation$7,956
Total Calculated Compensation$798,956
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $101.30 USD +3.40


Stanley T. Crooke M.D., Ph.D.Founder, Executive Chairman, Chief Executive Officer, President, Chairman of Science/Medical Committee and Member of Agenda Committee
Isis Pharmaceuticals, Inc.
Edward M. Kaye M.D., Ph.D.Interim Chief Executive Officer, Chief Medical Officer and Senior Vice President
Sarepta Therapeutics, Inc.
Mark W. Schwartz Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
Mark Joseph Murray Ph.D.Chief Executive Officer, President and Director
Arbutus Biopharma Corporation
Paul C. Grint M.D.Chief Executive Officer, President and Director
Regulus Therapeutics Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at